1CM
RVNC

1492 Capital Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

1492 Capital Management’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-38,966
Closed -$1.39M – 98
2017
Q4 		$1.39M Buy
+38,966
New +$1.12M 1.09% 29

Other funds holding RVNC

EWM
Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
NCM
NovaQuest Capital Management Raleigh, North Carolina $54.3M AUM 163.39% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

1492 Capital Management's RVNC Position: Q1 2018 in Review

1492 Capital Management sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2018, closing a stake of 38,966 shares — an estimated $1.39M sold.

1492 Capital Management first reported a position in RVNC in Q4 2017 and held it in 1 quarter. The position peaked at $1.39M in Q4 2017. 120 funds tracked by Wall St. Rank hold RVNC as of Q1 2018.

  • 1492 Capital Management reported no remaining Revance Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • 1492 Capital Management sold 38,966 Revance Therapeutics, Inc. shares in Q1 2018, an estimated $1.39M.
  • 1492 Capital Management first reported a position in Revance Therapeutics, Inc. in Q4 2017 and held it in 1 quarter.
  • 1492 Capital Management's Revance Therapeutics, Inc. position peaked at $1.39M in Q4 2017.
  • 120 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2018.

Based on 1492 Capital Management's 13F filing for Q1 2018, filed 14 May 2018.